DEFA14A filed Apr 30, 2026 at 17:22 ET
Syndax Pharmaceuticals filed a DEFA14A (additional definitive proxy soliciting materials) on April 30, 2026. The filing is a definitive additional proxy statement, but the actual document content is unavailable, only the SEC filing header and metadata are provided. The filing type suggests ongoing proxy solicitation activity, but without document text, no specific proposals, activist demands, or financial figures can be extracted.